This alters GTP hydrolysis through interfering with the gamma‐phosphate of GTP and causes constitutive activation of the MEK/MAPK as well as activation of PI3K and RAS‐like protein GEFs signaling pathways, which makes NRAS‐mutant melanomas more aggressive and more likely to develop resistance against treatment (Downward, 2015; Fig 1A). The gene discussed is NRAS; the disease is melanoma.